Jennifer Keating Litton, M.D., MHCM

Peer-Reviewed Articles

1. Yam C, Rauch GM, Rahman T, Karuturi M, Ravenberg E, White J, Clayborn A, McCarthy P, Abouharb S, Lim B, Litton JK, Ramirez DL, Saleem S, Stec J, Symmans WF, Huo L, Damodaran S, Sun R, Moulder SL. A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer. Invest New Drugs 39(2):509-515, 2021. PMID: 32984932.
2. Abdelhafez AH, Musall BC, Adrada BE, Hess K, Son JB, Hwang KP, Candelaria RP, Santiago L, Whitman GJ, Le-Petross HT, Moseley TW, Arribas E, Lane DL, Scoggins ME, Leung JWT, Mahmoud HS, White JB, Ravenberg EE, Litton JK, Valero V, Wei P, Thompson AM, Moulder SL, Pagel MD, Ma J, Yang WT, Rauch GM. Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). Breast Cancer Res Treat 185(1):1-12, 2021. PMID: 32920733.
3. Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Goggins M, Hutton ML, CGC, Karlan BY, Khan S, Klein C, Kohlmann W, CGC, Kurian AW, Laronga C, Litton JK, Mak JS, LCGC, Menendez CS, Merajver SD, Norquist BS, Offit K, Pederson HJ, Reiser G, CGC, Senter-Jamieson L, CGC, Shannon KM, Shatsky R, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Yurgelun MB, Darlow SD, Dwyer MA. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 19(1):77-102, 2021. PMID: 33406487.
4. Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gonçalves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, Roché H, Im YH, Eiermann W, Quek RGW, Usari T, Lanzalone S, Czibere A, Blum JL, Martin M, Ettl J. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol 31(11):1526-1535, 2020. PMID: 32828825.
5. Elmeliegy M, Yu Y, Litton JK, Czibere A, Wilson GG, Tudor IC, Zheng J, Wang DD. Exposure-Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials. J Clin Pharmacol 60(10):1334-1343, 2020. e-Pub 2020. PMID: 32468645.
6. Yu Y, Elmeliegy M, Litton JK, Tudor IC, Czibere A, Zheng J, Wang DD. Talazoparib Exposure-Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA Trial. J Clin Pharmacol 60(10):1324-1333, 2020. PMID: 32468579.
7. Clifton GT, Hale D, Vreeland TJ, Hickerson AT, Litton JK, Alatrash G, Murthy RK, Qiao N, Philips AV, Lukas JJ, Holmes JP, Peoples GE, Mittendorf EA. Results of a randomized phase IIb trial of nelipepimut-S + trastuzumab vs trastuzumab to prevent recurrences in high-risk HER2 low-expressing breast cancer patients. Clin Cancer Res 26(11):2515-2523, 2020. e-Pub 2020. PMID: 32071118.
8. Brown TA, Mittendorf EA, Hale DF, Myers JW, Peace KM, Jackson DO, Greene JM, Vreeland TJ, Clifton GT, Ardavanis A, Litton JK, Shumway NM, Symanowski J, Murray JL, Ponniah S, Anastasopoulou EA, Pistamaltzian NF, Baxevanis CN, Perez SA, Papamichail M, Peoples GE. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence. Breast Cancer Res Treat 181(2):391-401, 2020. e-Pub 2020. PMID: 32323103.
9. Tung NM, Boughey JC, Pierce LJ, Robson ME, Bedrosian I, Dietz JR, Dragun A, Gelpi JB, Hofstatter EW, Isaacs CJ, Jatoi I, Kennedy E, Litton JK, Mayr NA, Qamar RD, Trombetta MG, Harvey BE, Somerfield MR, Zakalik D. Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. J Clin Oncol 38(18):2080-2106, 2020. e-Pub 2020. PMID: 32243226.
10. Brown TA, Mittendorf EA, Hale DF, Myers JW, Peace KM, Jackson DO, Greene JM, Vreeland TJ, Clifton GT, Ardavanis A, Litton JK, Shumway NM, Symanowski J, Murray JL, Ponniah S, Anastasopoulou EA, Pistamaltzian NF, Baxevanis CN, Perez SA, Papamichail M, Peoples GE. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence. Breast Cancer Res Treat 181(2):391-401, 2020. e-Pub 2020. PMID: 32323103.
11. Pal T, Agnese D, Daly M, La Spada A, Litton J, Wick M, Klugman S, Esplin ED, Jarvik GP, Professional Practice and GuidelinesCommittee. Points to consider: Is there evidence to support BRCA1/2 and other inherited breast cancer genetic testing for all breast cancer patients? A statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med 22(4):681-685, 2020. e-Pub 2019. PMID: 31831881.
12. Emborgo TS, Saporito D, Muse KI, Barrera AMG, Litton JK, Lu KH, Arun BK. Prospective evaluation of universal BRCA testing for women with triple-negative breast cancer. JNCI Cancer Spectr eCollection-20;4(2):pkaa002. doi: 10.1093/jncics/pkaa002(2):pkaa002, 2020. e-Pub 2020. PMID: 32211581.
13. Daly MB, Pilarski R, Yurgelun MB, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Garber JE, Goggins M, Hutton ML, Khan S, Klein C, Kohlmann W, Kurian AW, Laronga C, Litton JK, Mak JS, Menendez CS, Merajver SD, Norquist BS, Offit K, Pal T, Pederson HJ, Reiser G, Shannon KM, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Dwyer MA, Darlow SD. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. J Natl Compr Canc Netw 18(4):380-391, 2020. PMID: 32259785.
14. Hurvitz SA, Gonçalves A, Rugo HS, Lee KH, Fehrenbacher L, Mina LA, Diab S, Blum JL, Chakrabarti J, Elmeliegy M, DeAnnuntis L, Gauthier E, Czibere A, Tudor IC, Quek RGW, Litton JK, Ettl J. Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial. Oncologist 25(3):e439-e450, 2020. e-Pub 2019. PMID: 32162822.
15. Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Barcenas CH, Valero V, Whitman GJ, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Helgason T, Ibrahim N, Piwnica-Worms H, Moulder SL, Arun BK. Neoadjuvant talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant. J Clin Oncol 38(5):388-394, 2020. e-Pub 2019. PMID: 31461380.
16. Chu YY, Yam C, Chen MK, Chan LC, Xiao M, Wei YK, Yamaguchi H, Lee PC, Han Y, Nie L, Sun X, Moulder SL, Hess KR, Wang B, Hsu JL, Hortobagyi GN, Litton J, Chang JT, Hung MC. Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer. Am J Cancer Res 10(2):648-661, 2020. PMID: 32195033.
17. Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Mina LA, Diab S, Woodward NE, Yerushalmi R, Goodwin A, Blum JL, Martin M, Quek RGW, Tudor IC, Bhattacharyya H, Gauthier E, Litton JK, Eiermann W. Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy. JNCI Cancer Spectr 4(1):pkz085, 2020. e-Pub 2019. PMID: 32337496.
18. Xing Y, Lin NU, Maurer MA, Chen H, Mahvash A, Sahin A, Akcakanat A, Li Y, Abramson V, Litton J, Chavez-MacGregor M, Valero V, Piha-Paul SA, Hong D, Do KA, Tarco E, Riall D, Eterovic AK, Wulf GM, Cantley LC, Mills GB, Doyle LA, Winer E, Hortobagyi GN, Gonzalez-Angulo AM, Meric-Bernstam F. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res 21(1):78, 2019. e-Pub 2019. PMID: 31277699.
19. Clifton K, Min Y, Kimmel J, Litton J, Tripathy D, Karuturi M. Progression-free survival (PFS) and toxicities of palbociclib in a geriatric population. Breast Cancer Res Treat 175(3):667-674, 2019. e-Pub 2019. PMID: 30835017.
20. Garber HR, Litton JK. Integrating poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer. Curr Opin Oncol 31(3):247-255, 2019. PMID: 30789866.
21. Clifton GT, Peace KM, Holmes JP, Vreeland TJ, Hale DF, Herbert GS, Litton JK, Murthy RK, Lukas J, Peoples GE, Mittendorf Elizabeth A. Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors. Clin Immunol 201:48-54, 2019. e-Pub 2019. PMID: 30817999.
22. Adams S, Gatti-Mays ME, Kalinsky K, Korde LA, Sharon E, Amiri-Kordestani L, Bear H, McArthur HL, Frank E, Perlmutter J, Page DB, Vincent B, Hayes JF, Gulley JL, Litton JK, Hortobagyi GN, Chia S, Krop I, White J, Sparano J, Disis ML, Mittendorf EA. Current landscape of immunotherapy in breast cancer: A review. JAMA Oncol. e-Pub 2019. PMID: 30973611.
23. Litton JK, Burstein HJ, Turner NC. Molecular testing in breast cancer. Am Soc Clin Oncol Educ Book 39:e1-e7, 2019. e-Pub 2019. PMID: 31099622.
24. Sinn BV, Fu C, Lau R, Litton J, Tsai TH, Murthy R, Tam A, Andreopoulou E, Gong Y, Murthy R, Gould R, Zhang Y, King TA, Viale A, Andrade V, Giri D, Salgado R, Laios I, Sotiriou C, Marginean EC, Kwiatkowski DN, Layman RM, Booser D, Hatzis C, Vicente Valero V, Fraser Symmans W. SETER/PR: A robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer. NPJ Breast Cancer 5:16, 2019. e-Pub 2019. PMID: 31231679.
25. Murthy RK, Raghavendra AS, Hess KR, Fujii T, Lim B, Barcenas CH, Zhang H, Chavez-Mac-Gregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson AM, Valero V, Moulder SL, Tripathy D, Ueno NT. Neoadjuvant pertuzumab-containing regimens improve pathologic complete response rates in stage II to III HER-2/neu-positive breast cancer: A retrospective, single institution experience. Clin Breast Cancer 18(6):e1283-e1288, 2018. e-Pub 2018. PMID: 30077429.
26. Jackson DO, Trappey FA, Clifton GT, Vreeland TJ, Peace KM, Hale DF, Litton JK, Murray JL, Perez SA, Papamichail M, Mittendorf EA, Peoples GE. Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence-implications for vaccine trial design. Clin Immunol 195:28-35, 2018. e-Pub 2018. PMID: 30025819.
27. Ettl J, Quek RGW, Lee KH, Rugo HS, Hurvits S, Goncalves A, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roche H, Im YH, Markova D, Bhattacharyya H, Hannah AL, Eirmann W, Blum JL, Litton JK. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: Patient-reported outcomes from the EMBRACA phase III trial. Annls of Oncol 29(9):1939-47, 2018. PMID: 30124753.
28. Litton JK, Rugo HS, Ettl J, Hurvitz SA, Goncalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roche H, Im YH, Quek RGW, Markova D, Tudor JC, Hannak AL, Eiermann W, Blum JL. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 379(8):753-763, 2018. e-Pub 2018. PMID: 30110579.
29. Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, Li CW, Kim T, Chang SS, Lee HH, Hsu JL, Wang HL, Kuo CW, Chang WC, Hadad S, Purdie CA, McCoy AM, Cai S, Tu Y, Litton JK, Mittendorf EA, Moulder SL, Symmans WF, Thompson AM, Piwnica-Worms H, Chen CH, Khoo KH, Hung MC. Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of pd-l1 71(4):606-620 e7, 2018. PMID: 30118680.
30. Clifton K, Barnett C, Martinez A, Karuturi M, Saleem S, Litton J. Severe hyponatremia following cyclophosphamide infusion in breast cancer patients. Breast J 24(4):691-692, 2018. e-Pub 2018.
31. Vreeland TJ1, Litton JK2, Qiao N3, Philips AV4, Alatrash G5, Hale DF6, Jackson DO7, Peace KM8, Greene JM9, Berry JS10, Clifton GT11, Peoples GE12, Mittendorf EA. Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune response. Clin Immunol 192:6-13, 2018. e-Pub 2018. PMID: 29574039.
32. Clifton K, Gutierrez-Barrera A, Ma J, Bassett R Jr, Litton J, Kuerer H, Moulder S, Albarracin C, Hortobagyi G, Arun B. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations. Breast Cancer Res Treat 170(1):101-109, 2018. e-Pub 2018. PMID: 29470805.
33. Kogawa T, Fujii T, Fouad TM, Liu DD, Harano K, Masuda H, Iwase T, Barnett C, Park YS, Lim B, Tripathy D, Litton JK, Ueno NT. Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes. Breast Cancer Res Treat. e-Pub 2018. PMID: 29915946.
34. Elsayegh N, Webster RD, Gutierrez Barrera AM, Lin H, Kuerer HM, Litton JK, Bedrosian I, Arun BK. Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer. Cancer Med 7(6):2718-2726, 2018. e-Pub 2018. PMID: 29733510.
35. Carey JP, Karakas C, Bui T, Chen X, Vijayaraghavan S, Zhao Y, Wang J, Mikule K, Litton JK, Hunt KK, Keyomarsi K. Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple negative breast cancer. Cancer Res 78(3):742-57, 2018. e-Pub 2017. PMID: 29180466.
36. Chambers MS, Rugo HS, Litton JK, Meiller TF.. Stomatitis associated with mTOR inhibition: A review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast cancer. J Am Dent Assoc. e-Pub 2018. PMID: 29439772.
37. Parkes A, Clifton K, Al-Awadhi A, Oke O, Warneke CL, Litton JK, Hortobagyi GN. Characterization of bone only metastasis patients with respect to tumor subtypes. NPJ Breast Cancer 4(2), 2018. e-Pub 2018. PMID: 29387785.
38. Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, Adrada BE, Moulder SL, Barcenas CH, Valero V, Gomez JS, Mittendorf EA, Thompson A, Helgason T, Mills GB, Piwnica-Worms H, Arun BK. A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. NPJ Breast Cancer 3:49, 2017. PMID: 29238749.
39. Bashour SI, Doostan I, Keyomarsi K, Valero V, Ueno NT, Brown PH, Litton JK, Koenig KB, Karuturi M, Abouharb S, Tripathy D, Moulder-Thompson SL, Ibrahim NK.. Rapid breast cancer disease progression following cyclin dependent kinase 4 and 6 inhibitor discontinuation. J Cancer 8(11):2004-9, 2017. PMID: 28819400.
40. Cropper C, Woodson A, Arun B, Barcenas C, Litton J, Noblin S, Liu D, Park M, Daniels M. Evaluating the NCCN clinical criteria for recommending BRCA1 and BRCA2 genetic testing in breast cancer patients. J Natl Compr Canc Netw 15(6):797-803, 2017. PMID: 28596260.
41. Parkes A, Arun BK, Litton JK. Systemic treatment strategies for patients with hereditary breast cancer syndromes. Oncologist 22(6):655-666, 2017. PMID: 28469042.
42. Rugo HS, Seneviratne L, Beck T, Glaspy JA, Peguero JA, Pluard TJ, Dhillon N, Hwang LC, Nangia C, Mayer IA, Meiller TF, Chambers MS, Sweetman RW, Sabo R, Litton JK. Prevention of everolimus/exemestane–related stomatitis in women with hormone receptor–positive metastatic breast cancer using dexamethasone mouthwash: Results from the phase 2, single-arm SWISH trial. Lancet Onc. e-Pub 2017. PMID: 28314691.
43. Travis Clifton G, Litton JK, Arrington K, Ponniah S, Ibrahim NK, Gall V, Alatrash G, Peoples GE, Mittendorf EA. Results of a phase Ib trial of combination immunotherapy with a CD8+ T cell eliciting vaccine and trastuzumab in breast cancer patients. Ann Surg Oncol 24(8):2161-7, 2017. e-Pub 2017. PMID: 28315060.
44. Daly MB, Pilarski R, Berry M, Buys SS, Farmer M, Friedman S, Garber JE, Kauff ND, Khan S, Klein C, Kohlmann W, Kurian A, Litton JK, Madlensky L, Merajver SD, Offit K, Pal T, Reiser G, Shannon KM, Swisher E, Vinayak S, Voian NC, Weitzel JN, Wick MJ, Wiesner GL, Dwyer M, Darlow S. NCCN guidelines insights: Genetic/familial high-risk assessment: Breast and ovarian, version 2.2017. J Natl Compr Canc Netw 15(1):9-20, 2017. PMID: 28040716.
45. Basho RK, Gagliato DM, Ueno NT, Wathoo C, Chen H, Shariati M, Wei C, Alvarez RH, Moulder SL, Sahin AA, Roy-Chowdhuri S, Chavez-MacGregor M, Litton JK, Valero V, Luthra R, Zeng J, Shaw KR, Mendelsohn J, Mills GB, Tripathy D, Meric-Bernstam F. Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget. e-Pub 2016. PMID: 27806348.
46. Mittendorf EA, Ardavanis A, Symanowski J, Murray JL, Shumway NM, Litton JK, Hale DF, Perez SA, Anastasopoulou EA, Pistamaltzian NF, Ponniah S, Baxevanis CN, von Hofe E, Papamichail M, Peoples GE. Primary analysis of a prospective, randomised, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence. Ann Oncol 27(7):1241-8, 2016. e-Pub 2016. PMID: 27029708.
47. Streff H, Profato J, Ye Y, Nebgen D, Peterson SK, Singletary C, Arun BK, Litton JK. Cancer incidence in first and second degree relatives of BRCA1 and BRCA2 mutation carriers. Oncologist 21(7):869-74, 2016. e-Pub 2016. PMID: 27306910.
48. Arun B, Gong Y, Liu D, Litton JK, Gutierrez-Barrera AM, Jack Lee J, Vornik L, Ibrahim NK, Cornelison T, Hortobagyi GN, Heckman-Stoddard BM, Koenig KB, Alvarez RR, Murray JL, Valero V, Lippman SM, Brown P, Sneige N. Phase I biomarker modulation study of storvastatin in women at increased risk for breast cancer. Breast Cancer Res Treat, 2016. PMID: 27287781.
49. Vila J, Mittendorf EA, Farante G, Bassett RL, Veronesi P, Galimberti V, Peradze N, Stauder MC, Chavez-MacGregor M, Litton JF, Huo L, Kuerer HM, Hunt KK, Caudle AS. Nomograms for predicting axillary response to neoadjuvant chemotherapy in clinically node-positive patients with breast cancer. Ann Surg Oncol, 2016. e-Pub 2016. PMID: 27216742.
50. Elsayegh N, Barrera AM, Muse KI, Lin H, Kuerer HM, Helm M, Litton JK, Arun BK. Evaluation of BRCAPRO risk assessment model in patients with ductal carcinoma in situ who underwent clinical BRCA genetic testing. Front Genet 27(7):71, 2016. PMID: 27200080.
51. Swisher SK, Vila J, Tucker SL, Bedrosian I, Shaitelman SF, Litton JK, Smith BD, Caudle AS, Kuerer HM, Mittendorf EA. Local-regional control according to breast cancer subtype and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Annals of Surg Onc 23(3):749-56, 2016. e-Pub 2015. PMID: 26511263.
52. Daly MB, Pilarski R, Axilbund JE, Berry M, Buys SS, Crawford B, Farmer M, Friedman S, Garber JE, Khan S, Klein C, Kohlmann W, Kurian A, Litton JK, Madlensky L, Marcom PK, Merajver SD, Offit K, Pal T, Rana H, Reiser G, Robson ME, Shannon KM, Swisher E, Voian NC, Weitzel JN, Whelan A, Wick MJ, Wiesner GL, Dwyer M, Kumar R, Darlow S. Genetic/familial high-risk assessment: Breast and ovarian, version 2.2015. J Natl Compr Canc Netw 14(2):153-62, 2016. PMID: 26850485.
53. Kehl KL, Shen C, Litton JK, Arun B, Giordano SH. Rates of BRCA1/2 mutation testing among young survivors of breast cancer. Breast Cancer Res Treat 155(1):165-73, 2016. e-Pub 2015. PMID: 26706041.
54. Meric-Bernstam F, Brusco L, Daniels M, Wathoo C, Bailey A, Strong L, Shaw K, Lu K, Qi Y, Zhao H, Lara-Guerra H, Litton J, Arun B, Eterovic AK, Aytac U, Routbort M, Subbiah V, Janku F, Davies MA, Kopetz S, Mendelsohn J, Mills GB, Chen K. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Ann of Oncol 27(5):795-800, 2016. e-Pub 2016. PMID: 26787237.
55. Gonzalez-Angulo AM, Lei X, Alvarez RH, Green MC, Murray JL, Valero V, Koenig KB, Ibrahim NK, Litton JK, Nair L, Krishnamurthy S, Hortobagyi GN, Meric-Bernstam F. Phase II randomized study of ixabepilone vs. observation in patients with significant residual disease after neoadjuvant systemic therapy for HER2-negative breast cancer. Clin Breast Cancer 15(5):325-31, 2015. PMID: 25913905.
56. Sanford RA, Song J, Gutierrez-Barrera AM, Profato J, Woodson A, Litton JK, Bedrosian I, Albarracin CT, Valero V, Arun B.. High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors. Cancer, 2015. e-Pub 2015. PMID: 26280679.
57. Bayraktar S, Jackson M, Gutierrez Barrera AM, Liu D, Meric-Bernstam F, Brandt A, Woodson A, Litton J, Lu KH, Valero V, Arun BK. Genotype-phenotype correlations by ethnicity and mutation location in BRCA mutation carriers. Breast J 21(3):260-7, 2015. e-Pub 2015. PMID: 25789811.
58. De Lu, F. Eckhardt B, Lim B, Moulder S, Litton J, Ueno NT. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?. Oncotarget, 2015. e-Pub 2015. PMID: 25973541.
59. Elsayegh N, Profato J, Barrera AM, Lin H, Kuerer HM, Ardic C, Litton JK, Tripathy D, Arun BK. Predictors that influence election of contralateral prophylactic mastectomy among women with ductal carcinoma in situ who are BRCA-negative. J Cancer 6(7):610-5, 2015. PMID: 26078790.
60. Parinyanitikul N, Lei X, Chavez-MacGregor M, Liu S, Mittendorf EA, Litton JK, Woodward W, Zhang AH, Hortobagyi GN, Valero V, Meric-Bernstam F, Gonzalez-Angulo AM. Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes. Clin Breast Cancer 15(2):153-60, 2015. e-Pub 2014. PMID: 25454687.
61. Mitri ZI, Jackson M, Garby C, Song J, Giordano SH, Hortobagyi GN, Singletary CN, Hasmi SS, Arun BK, Litton JK. BRCAPRO 6.0 model in male patients presenting for BRCA testing. Oncologist 20(6):593-7, 2015. PMID: 25948675.
62. Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, Arun BK, Litton JK. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 121(2):269-75, 2015. e-Pub 2014. PMID: 25224030.
63. Kogawa T, Fouad TM, Wei C, Masuda H, Kai K, Fujii T, El-Zein R, Chavez-MacGregor M, Litton JK, Brewster A, Alvarez RH, Hortobagyi GN, Valero V, Theriault R, Ueno NT. Association of body mass index changes during neoadjuvant chemotherapy with pathologic complete response and clinical outcomes in patients with locally advanced breast cancer. J Cancer 6(4):310-8, 2015. PMID: 25767600.
64. Woodson AH, Muse KI, Lin H, Jackson M, Mattair DN, Schover L, Woodard T, McKenzie L, Theriault RL, Hortobágyi GN, Arun B, Peterson SK, Profato J, Litton JK. Breast cancer, BRCA mutations, and attitudes regarding pregnancy and preimplantation genetic diagnosis. Oncologist 19(8):797-804, 2014. e-Pub 2014. PMID: 24951607.
65. Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam F. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer. Ann Oncology 25(6):1122-7, 2014. e-Pub 2014. PMID: 24669015.
66. Jackson SA, Davis AA, Li J, Yi N, McCormick SR, Grant C, Fallen T, Crawford B, Loranger K, Litton J, Arun B, Vande Wydeven K, Sidani A, Farmer K, Sanders M, Hoskins K, Nussbaum R, Esserman L, Garber JE, Kaklamani VG; the Northwestern Cancer Genetics Group. Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2. Cancer 120(10):1557-64, 2014. e-Pub 2014. PMID: 24522996.
67. Elsayegh N, Kuerer HM, Lin H, Gutierrez Barrera AM, Jackson M, Muse KI, Litton JK, Albarracin C, Afrough A, Hortobagyi GN, Arun BK. Predictors that Influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing. Ann Surg Oncol, 2014. e-Pub 2014. PMID: 24796968.
68. Morrow PK, Broxson AC, Munsell MF, Basen-Enquist K, Rosenblum CK, Schover L, Nguyen LH, Hsu L, Castillo L, Hahn KM, Litton JK, Mattair DM, Hortobagyi GN. Effect of age and race upon quality of young breast cancer survivors. Clin Breast Cancer 14(2):e 21-31, 2014. e-Pub 2013. PMID: 24461458.
69. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, Alatrash G. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2(4):361-70. e-Pub 2014. PMID: 24764583.
70. André F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, Yap YS, Papai Z, Lang I, Armstrong A, Lerzo G, White M, Shen K, Litton J, Chen D, Zhang Y, Ali S, Taran T, Gianni L. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): A randomized, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. e-Pub 2014. PMID: 24742739.
71. Chen JQ, Bao Y, Lee J, Murray JL, Litton JK, Xiao L, Zhou R, Wu Y, Shen XY, Zhang H, Sahin AA, Katz RL, Bondy ML, Berinstein NL, Hortobagyi GN, Radvanyi LG. Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), A GATA family transcription factor, in early-stage breast cancer. Ann Oncol 24(10):2534-42, 2013. e-Pub 2013. PMID: 23729783.
72. Weksberg DC, Allen PK, Hoffman KE, Litton JK, Strom EA, Shah RR, Kuerer HM, Hunt KK, Buchholz TA, Mittendorf EA. Outcomes and predictive factors for salvage therapy after local--regional recurrence following neoadjuvant chemotherapy and breast conserving therapy. Ann Surg Oncol 20(11):3430-7, 2013. e-Pub 2013. PMID: 23720073.
73. Yennurajalingam S, Frisbee-Hume S, Palmer JL, Delgado-Guay MO, Bull J, Phan AT, Tannir NM, Litton JK, Reddy A, Hui D, Dalal S, Massie L, Reddy SK, Bruera E. Reduction of cancer-related fatigue with dexamethasone: A double-blind, randomized, placebo-controlled trial in advanced cancer patients. J Clin Oncol 31(25):3076-82, 2013. e-Pub 2013. PMID: 23897970.
74. Rich TA, Liu M, Etzel CJ, Bannon SA, Mork ME, Ready K, Saraiya DS, Grubbs EG, Perrier ND, Lu ND, Lu KH, Arun BK, Woodard TL, Schover LR, Litton JK. Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes. Fam Cancer 13(2):291-9, 2013. PMID: 24072553.
75. Chae YK, Brown EN, Lei X, Melhem-Bertrandt A, Giordano SH, Litton JK, Hortobagyi GN, Gonzalez-Angulo AM, Chavez-MacGregor M. Use of ACE inhibitors and angiotensin receptor blockers and primary breast cancer outcomes. J Cancer 4(7):549-56, 2013. PMID: 23983819.
76. Woodson AH, Profarto JL, Muse KI, Litton JK. Breast cancer in the young: Role of the geneticist. J Thorac Dis 5(Suppl 1):S19-26, 2013. PMID: 23819023.
77. Bayraktar S, Gutierrez-Barrera AM, Lin H, Elsayegh N, Tasbas T, Litton JK, Ibrahim NK, Morrow PK, Green M, Valero V, Booser DJ, Hortobagyi GN, Arun BK.. Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations. J Clin Exp Mets 30(5):631-42, 2013. e-Pub 2013. PMID: 23370825.
78. Litton JK, Warneke CL. Hahn KM, Palla SL, Kuerer HM, Perkins GH, Mittendorf EA, Barnett C, Gonzalez-Angulo AM, Hortobagyi GN, Theriault RL. Case control study of women treated with chemotherapy for breast cancer during pregnancy as compared with non-pregnant breast cancer patients. Oncologist 18(4):369-76, 2013. e-Pub 2013. PMID: 23576478.
79. Meric-Bernstam F, Gutierrez-Barrera AM, Litton J, Mellor-Crummey L, Ready K, Gonzalez-Angulo AM, Lu KH, Hortobagyi GN, Arun BK. Genotype in BRCA-associated breast cancers. Breast J 19(1):87-91, 2013. e-Pub 2012. PMID: 23231005.
80. Bayraktar S, Gutierrez Barrera AM, Liu D, Pusztai L, Litton J, Valero V, Hunt K, Hortobagyi GN, Wu Y, Symmans F, Arun B. USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancer. Cancer J 19(1):10-7, 2013. PMID: 23337751.
81. Kim MM, Allen P, Gonzalez-Angulo AM, Woodward WA, Meric-Bernstam F, Buzdar AU, Hunt KK, Kuerer HM, Litton JK, Hortobagyi GN, Buchholz TA, Mittendorf EA. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol 24(8):1999-2004, 2013. PMID: 23562929.
82. Dawood S, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM. Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. Cancer 118(19):4652-9, 2012. e-Pub 2012. PMID: 22359359.
83. Dawood S, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM. Impact of body mass index on survival outcome among women with early stage triple-negative breast cancer. Clin Breast Cancer 12(5):364-72, 2012. PMID: 23040004.
84. Kuerer HM, Lari SA, Arun BK, Hu CY, Brewster A, Mittendorf EA, Albarracin CT, Babiera GV, Caudle AS, Wagner JL, Litton JK, Bedrosian I, Meric-Bernstam F, Lucci A, Hunt KK. Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat 133(3):1131-41, 2012. e-Pub 2012. PMID: 22392043.
85. Caudle AS, Yu TK, Tucker SL, Bedrosian I, Litton JK, Gonzalez-Angulo AM, Hoffman K, Meric-Bernstam F, Hunt KK, Buchholz TA, Mittendorf EA. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res 14(3):R83, 2012. PMID: 22621334.
86. Bayraktar S, Elsayegh N, Gutierrez Barrera AM, Lin H, Kuerer H, Tasbas T, Muse KI, Ready K, Litton JK, Meric-Bernstam F, Hortobagyi GN, Albarracin CT, Arun B. Predictive factors for BRCA1/2 mutations in women with ductal carcinoma in situ. Cancer 118(6):1515-22, 2012. PMID: 22009639.
87. Bayraktar S, Hernandez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, Hortobagyi GN, Gonzalez-Angulo AM. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 118(5):1202-11, 2012. e-Pub 2011. PMID: 21800293.
88. Melhem-Bertrandt A, Bojadzieva J, Ready KJ, Obeid E, Liu DD, Gutierrez-Barrera AM, Litton JK, Olopade OI, Hortobagyi GN, Strong LC, Arun BK. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer 118(4):908-13, 2012. e-Pub 2011. PMID: 21761402.
89. Litton JK, Ready K, Chen H, Gutierrez-Barrera A, Etzel CJ, Meric-Bernstam F, Gonzalez-Angulo AM, Le-Petross H, Lu K, Hortobagyi GN, Arun BK. Earlier age of onset of BRCA mutation-related cancers in subsequent generations. Cancer 118(2):321-5, 2012. e-Pub 2011. PMID: 21913181.
90. Chavez-MacGregor M, Brown E, Lei X, Litton JK, Meric-Bernstram F, Mittendorf E, Hernandez L, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Bisphosphonates and pathologic complete response to taxane and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer. Cancer 118(2):326-32, 2012. e-Pub 2011. PMID: 21590688.
91. Del Fabbro E, Parsons H, Warneke CL, Pulivarthi K, Litton JK, Dev R, Palla SL, Brewster A, Bruera E. The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer. The Oncologist 17(10):1240-5, 2012. e-Pub 2012. PMID: 22903527.
92. Ready K, Arun BK, Schmeler KM, Uyei A, Litton JK, Lu KH, Sun CC, Peterson SK. Communication of BRCA1 and BRCA2 genetic test results to health care providers following genetic testing at a tertiary care center. Fam Cancer 10(4):673-9, 2011. PMID: 21681553.
93. Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK, Lin E, Albarracin CT, Meric-Bernstam F, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat 130(1):145-53, 2011. e-Pub 2011. PMID: 21830012.
94. Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and non-carriers: A single institution experience. J Clin Oncol 29(28):3739-46, 2011. e-Pub 2011. PMID: 21900106.
95. Theriault RL, Litton JK, Mittendorf EA, Chen H, Meric-Bernstam F, Chavez-Macgregor M, Morrow PK, Woodward WA, Sahin A, Hortobagyi GN, Gonzalez-Angulo AM. Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype. Clin Breast Cancer 11(5):325-31, 2011. e-Pub 2011. PMID: 21764391.
96. Adkins FC, Gonzalez-Angulo AM, Lei X, Hernandez-Aya LF, Mittendorf EA, Litton JK, Wagner J, Hunt KK, Woodward WA, Meric-Bernstam F. Triple-negative breast cancer is not a contraindication for breast conservation. Ann Surg Oncol 18(11):3164-73, 2011. e-Pub 2011. PMID: 21947595.
97. Caudle AS, Hunt KK, Kuerer HM, Meric-Bernstam F, Lucci A, Bedrosian I, Babiera GV, Hwang RF, Ross MI, Feig BW, Hoffman K, Litton JK, Sahin AA, Yang W, Hortobagyi GN, Buchholz TA, Mittendorf EA. Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: A practice-changing trial. Ann Surg Oncol 18(9):2407-12, 2011. e-Pub 2011. PMID: 21327455.
98. Le-Petross HT, Whitman GJ, Atchley DP, Yuan Y, Gutierrez-Barrera A, Hortobagyi GN, Litton JK, Arun BK. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. Cancer 117(17):3900-7, 2011. e-Pub 2011. PMID: 21365619.
99. Sharma R, Rourke LL, Kronowitz SJ, Oh JL, Lucci A, Litton JK, Robb GL, Babiera GV, Mittendorf EA, Hunt KK, Kuerer HM. Management of local-regional recurrence following immediate breast reconstruction in patients with early breast cancer treated without postmastectomy radiotherapy. Plast Reconstr Surg 127(5):1763-72, 2011. PMID: 21532405.
100. Chen JQ, Bao Y, Litton J, Xiao L, Zhang HZ, Warneke CL, Wu Y, Shen X, Wu S, Katz RL, Sahin A, Bondy M, Murray JL, Radvanyi L. Expression and relevance of TRPS-1: A new GATA transcription factor in breast cancer. Horm Cancer 2(2):132-43, 2011. PMID: 21761336.
101. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK, Hortobagyi GN, Do KA, Mills GB, Meric-Bernstam F. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17(5):1082-9, 2011. e-Pub 2011. PMID: 21233401.
102. Valero V III, Kong AL, Hunt KK, Yi M, Hwang RF, Meric-Bernstam F, Bedrosian I, Ross MI, Babiera GV, Litton JK, Mittendorf EA. Sentinel lymph node dissection is technically feasible in older breast cancer patients. Clin Breast Cancer 10(6):477-82, 2010. PMID: 21147692.
103. Kelly CM, Krishnamurthy S, Bianchini G, Litton JK, Gonzalez-Angulo AM, Hortobagyi GN, Pusztai L. Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer 116(22):5161-7, 2010. PMID: 20665886.
104. Chavez-Macgregor M, Litton J, Chen H, Giordano SH, Hudis CA, Wolff AC, Valero V, Hortobagyi GN, Bondy ML, Gonzalez-Angulo AM. Pathologic complete response in breast cancer patients receiving anthracycline-and taxane-based neoadjuvant chemotherapy: Evaluating the effect of race/ethnicity. Cancer 116(17):4168-77, 2010. PMID: 20564153.
105. Yi M, Hunt KK, Arun BK, Bedrosian I, Barrera AG, Do KA, Kuerer HM, Babiera GV, Mittendorf EA, Ready K, Litton J, Meric Bernstam F. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res 3(8):1026-34, 2010. e-Pub 2010. PMID: 20647335.
106. Daly MB, Axilbund JE, Buys S, Crawford B, Farrell CD, Friedman S, Garber JE, Goorha S, Gruber SB, Hampel H, Kaklamani V, Kohlmann W, Kurian A, Litton JK, Marcom PK, Nussbaum R, Offit K, Pal T, Pasche B, Pilarski R, Reiser G, Shannon KM, Smith JR, Swisher E, Weitzel JN.. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw 8(5):562-94, 2010. PMID: 20495085.
107. Ready K, Litton JK, Arun BK. Clinical application of breast cancer risk assessment models. Future Oncol 6(3):355-65, 2010. PMID: 20222793.
108. Silberfein EJ, Hunt KK, Broglio K, Shen J, Sahin A, Le-Petross H, Oh J, Litton J, Hwang RF, Mittendorf EA. Clinicopathologic factors associated with involved margins after breast-conserving surgery for invasive lobular carcinoma. Clin Breast Cancer 10(1):52-8, 2010. PMID: 20133259.
109. Chen JQ, Litton JK, Xiao L, Zhang H-Z, Warneke CL, Wu, Y, Shen X, Wu S, Sahin A, Katz R, Bondy M, Hortobagyi GN, Berinstein NL, Murray JL, Radvanyi L.. Quantitative immunohistochemical analysis and prognostic significance of TRPS-1, A new GATA transcription factor family member, in breast cancer. Horm Cancer 1(1):21-33, 2010. e-Pub 2010. PMID: 21761348.
110. Dominici LS, Kuerer HM, Babiera G, Hahn KM, Perkins G, Middleton L, Ramirez MM, Yang W, Hortobagyi GN, Theriault RL, Litton JK. Wound complications from surgery in pregnancy-associated breast cancer (PABC). Breast Dis 31(1):1-5, 2010. PMID: 20519803.
111. Litton JK, Theriault RL. Breast cancer and pregnancy: Current concepts in diagnosis and treatment. Oncologist 15(12):1238-47, 2010. e-Pub 2010. PMID: 21147871.
112. Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, Peintinger F, Hanrahan EO, Sahin A, Guray M, Larsimont D, Feoli F, Stranzl H, Buchholz TA, Valero V, Theriault R, Piccart-Gebhart M, Ravdin PM, Berry DA, Hortobagyi GN. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27(34):5700-6, 2009. e-Pub 2009. PMID: 19884543.
113. Litton JK, Theriault RL, Gonzalez-Angulo AM. Breast cancer diagnosis during pregnancy. Women's Health (Lond Engl) 5(3):243-9, 2009. PMID: 19392610.
114. Litton JK, Westin SN, Ready K, Sun CC, Peterson SK, Meric-Bernstam F, Gonzalez-Angulo AM, Bodurka DC, Lu KH, Hortobagyi GN, Arun BK. Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer 115(8):1598-604, 2009. e-Pub 2009. PMID: 19280625.
115. Beadle BM, Woodward WA, Tucker SL, Outlaw ED, Allen PK, Oh JL, Strom EA, Perkins GH, Tereffe W, Yu TK, Meric-Bernstam F, Litton JK, Buchholz TA. Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach. Int J Radiat Oncol Biol Phys 73(3):734-44, 2009. e-Pub 2008. PMID: 18707822.
116. Beadle BM, Woodward WA, Middleton LP, Tereffe W, Strom EA, Litton JK, Meric-Bernstam F, Theriault RL, Buchholz TA, Perkins GH. The impact of pregnancy on breast cancer outcomes in women </=35 years. Cancer 115(6):1174-84, 2009. e-Pub 2009. PMID: 19204903.
117. Eralp Y, Smith TL, Altundag K, Kau SW, Litton JK, Valero V, Buzdar A, Hortobagyi GN, Arun B. Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger. J Cancer Res Clin Oncol 135(1):141-8, 2009. e-Pub 2008. PMID: 18581139.
118. Litton JK; Theriault RL, Gonzalez-Angulo AM. Breast Cancer diagnosis during pregnancy. Womens Health (Lond Engl) 5:243-249, 2009.
119. Litton JK, Gonzalez-Angulo AM, Warneke CL, Buzdar AU, Kau SW, Bondy M, Mahabir S, Hortobagyi GN, Brewster AM. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol 26(25):4072-7, 2008. PMID: 18757321.
120. Litton JK, Eralp Y, Gonzalez-Angulo AM, Broglio K, Uyei A, Hortobagyi GN, Arun B. Multifocal breast cancer in women < or =35 years old. Cancer 110(7):1445-50, 2007. PMID: 17676585.
121. Shapiro CL, Ervin T, Welles L, Azarnia N, Keating J, Hayes DF. Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group. J Clin Oncol 17(5):1435-41, 1999. PMID: 10334528.
122. Shapiro CL, Keating J, Angell JE, Janicek M, Gelman R, Hayes D, LeBoff MS. Monitoring therapeutic response in skeletal metastases using dual-energy X-ray absorptiometry: A prospective feasibility study in breast cancer patients. Cancer Invest 17(8):566-74, 1999. PMID: 10592763.
123. Shapiro CL, Ayash L, Webb IJ, Gelman R, Keating J, Williams L, Demetri G, Clark P, Elias A, Duggan D, Hayes D, Hurd D, Henderson IC. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral blood progenitor cells and filgrastim in advanced breast cancer patients. J Clin Oncol 15(2):674-83, 1997. PMID: 9053493.

Invited Articles

1. Tran G, Helm M, Litton J. Current approach to breast cancer risk reduction for women with hereditary predispositions to breast cancer. Current Breast Cancer Rep 8:165-174, 2016.
2. Rich TA, Woodson AH, Litton J, Arun B. Hereditary breast cancer syndromes and genetic testing. J Surg Oncol 111(1):66-80, 2015. PMID: 25381882.

Editorials

1. Woodard TL, Litton JK. Fertility preservation in women with breast cancer: Challenges and opportunities. Oncology (Williston Park) 27(6):544, 546, 2013. PMID: 23909068.
2. Litton JK, Gonzalez-Angulo AM. Evaluating breast cancer risk with genome-wide association studies: Is this approach patient ready?. J Clin Oncol 30(35):4288-9, 2012, 2012. PMID: 23109691.

Abstracts

1. Philippe Georges Aftimos, Mafalda Oliveira, Kevin Punie, Valentina Boni, Erika P. Hamilton, Ayca Gucalp, Payal D Shah, Maria J. de Miguel, Priyanka Sharma, Lisa Bauman, Eric Campeau, Sarah Attwell, Margo Snyder, Karen Norek, Emily Johnson, Michael H. Silverman, Sanjay Lakhotia, Susan M. Domchek, Jennifer Keating Litton, Mark E. Robson. A phase 1b/2 study of the BET inhibitor ZEN-3694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations. 2022 ASCO Annual Meeting, 2022.
2. Abuhadra N, Hess KR, Litton JK, Rauch GM, Thompson AM, Lim B, Adrada BE, Mittendorf EA, Damodaran S, Candelaria RP, Arun B, Yang WT, Ueno NT, Santiago L, Murthy RK, Ibrahim NK, Sahin AA, Symmans WF, Moulder SL, Huo L. Beyond TILs: Predictors of pathologic complete response (pCR) in triple-negative breast cancer (TNBC) patients with moderate tumor-infiltrating lymphocytes (TIL) receiving neoadjuvant therapy. 2019 ASCO Annual Meeting, 2019.
3. Diab S, Rugo HS, Mina LA, Puhalla S, Mahtani RL, Henry NL, Denduluri N, Yardley DA, Wang Y, Arruda LS, Tudor IC, Gauthier ER, Czibere AG, Litton JK, Hurvitz SA. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. 2019 ASCO Annual Meeting, 2019.
4. Ettl J, Hurvitz SA, Rugo HS, Lee KH, Mina LA, Woodward NE, Yerushalmi R, Diab S, Martin M, Tudor IC, Czibere AG, Gauthier ER, Litton JK, Goncalves A. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. 2019 ASCO Annual Meeting, 2019.
5. Hobbs E, Yang F, Kumar T, Contreras A, Cuentas ERP, Garber H, Scoggins M, Adrada BE, Whitman GJ, Arun B, Mittendorf EA, Litton JK. Tumor immune microenvironment (TiME) changes by multiplex IF staining in a pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation. 2019 ASCO Annual Meeting, 2019.
6. Seth S, Huo L, Rauch GM, Adrada BE, Piwnica-Worms H, Thompson AM, Mittendorf EA, Litton JK, Symmans WF, Draetta GF, Futrea Al, Moulder SL, Chang J. Delineating longitudinal patterns of response to neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS; NCT02276443). 2019 ASCO Annual Meeting, 2019.
7. Campf J, Clifton GT, Hale DF, Vreeland TJ, Hickerson A, Holmes JP, Litton JK, Murthy RK, Lukas JJ, Mittendorf EA, Peoples GE. Immunologic responses in triple-negative breast cancer patients in a randomized phase IIb trial of nelipepimut-S plus trastuzumab versus trastuzumab alone to prevent recurrence. 2019 ASCO Annual Meeting, 2019.
8. Seth S, Crespo J, Huo L, Thompson AM, Mittendorf EA, Hess KR, Litton JK, Rauch GM, Adrada BE, Damodaran S, Candelaria RP, Arun B, Yang WT, Santiago L, Murthy RK, Sahin AA, Symmans WF, Moulder SL, Ueno NT, Lim B. Evaluation of predictive biomarkers for AR therapy and to identify the LAR subtype of TNBC. 2019 ASCO Annual Meeting, 2019.
9. Damodaran S, Meric-Bernstam F, Hess KR, Litton JK, Raymond V, Lanman R, Ueno NT, Hamilton S, Wistuba II, Valero V, Moulder SL, Tripathy D. INTERACT- INTegrated Evaluation of Resistance and Actionability using Circulating Tumor DNA in hormone receptor (HR) positive metastatic breast cancers (MBC). 2018 CTRC-AACR San Antonio Breast Cancer Symposium, 2018.
10. Yam C, Raghavendra A, Hess KR, Adrada BE, Candelaria RP, Damodaran S, Gilcrease MZ, Helgason T, Hortobagyi GN, Huo L, Layman RM, Lim B, Litton JK, Mittendorf EA, Murthy RK, Piwnica-Worms H, Rauch GM, Santiago L, Symmans F, Thompson AM, Tripathy D, Ueno NT, Valero V, Barcenas CH, Moulder SL, Yang W. Impact of serial biopsies in triple-negative breast cancer patients receiving neoadjuvant systemic therapy. 2018 CTRC-AACR San Antonio Breast Cancer Symposium, 2018.
11. Clifton GT, Kemp Bohan PM, Hale DF, Myers JW, Brown TA, Holmes JP, Vreeland TJ, Litton JK, Murthy RK, Mittendorf EA, Peoples GE. Subgroups analysis of a multicenter, prospective, randomized, blinded phase 2b trial of trastuzumab + nelipeptimut-S (NeuVax) vs trastuzumab for prevention of recurrence in breast cancer patients. 2018 CTRC-AACR San Antonio Breast Cancer Symposium, 2018.
12. Litton J, Symmans F, Gogineni K, Saltzman M, Telli ML, Usha L, Chakrabarti J, Tudor IC, Quek RG, Czibere A. A phase 2, open-label, single-arm, multi-center study of talazoparib for neoadjuvant treatment of germline BRCA1/2 mutation patients with early-stage triple-negative breast cancer (TNBC). 2018 CTRC-AACR San Antonio Breast Cancer Symposium, 2018.
13. Murthy RK, Raghavendra AS, Hess KR, Barcenas CH, Lim B, Moulder SL, Giordano SH, Mittendorf EA, Thompson A, Ueno NT, Valero V, Litton JK, Tripathy D, Chavez-Macgregor M. 3-year relapse-free survival of stage II-III HER2-neu positive breast cancer treated with pertuzumab and trastuzumab-containing neoadjuvant therapy compared to trastuzumab-containing therapy. 2018 CTRC-AACR San Antonio Breast Cancer Symposium, 2018.
14. Clifton K, Kimmel J, Litton JK, Tripathy D, Karuturi Ms. Examining progression free survival (PFS), overall survival (OS), and toxicities of palbociclib in a geriatric population. 2017 ASCO Annual Meeting, 2018.
15. Westin SN, Litton JK, Williams RA, Shepherd CJ, Brugger W, Pease EJ, Soliman PT, Frumovitz MM, Levenback CF, Sood A, Meyer L, Moulder SL, Valero V, Saleem S, Rodriguez AM, Cyriac A, Engerman L, Samuel C, Mills GB, Coleman RL. Phase I trial of olaparib (PARP inhibitor) and vistusertib (mTORC1/2 inhibitor) in recurrent endometrial, ovarian and triple negative breast cancer. 2018 ASCO Annual Meeting, 2018.
16. Litton JK, Scoggins M, Hess KR, Adrada B, Barcenas CH, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Thompson AM, Whitman GJ, Ibrahim NK, Moulder SL, Schwartz-Gomez J, Mittendorf EA, Arun B. Neoadjuvant talazoparib (TALA) for operable breast cancer patients with a BRCA mutation (BRCA+). 2018 ASCO Annual Meeting, 2018.
17. Moulder SL, Hess KR, Candelaria RP, Rauch GM, Santiago L, Adrada B, Yang WT, Gilcrease MZ, Huo L, Stauder MC, Arun B, Layman RM, Murth RK, Damodaran S, Ueno NT, Thompson AM, Lim B, Mittendorf EA, Litton JK, Symmans WF. Precision neoadjuvant therapy (P-NAT): A planned interim analysis of a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS). 2018 ASCO Annual Meeting, 2018.
18. Yam C, Hess KR, Litton JK, Yang WT, Santiago L, Candelaria RP, Mittendorf EA, Murthy RK, Damodaran S, Helgason T, Huo L, Thompson AM, Barton M, Huang ML, Arribas EM, Lane DL, Rauch GM, Adrada BE, Gilcrease MZ, Moulder SL. Impact of metaplastic histology (MpBC) in triple-negative breast cancer (TNBC) patients (pts) receiving neoadjuvant systemic therapy (NAST). 2018 ASCO Annual Meeting, 2018.
19. Yap TA, Burris HA, Kummar S, Falchook GS, Pachynski RK, LoRusso P, Tykodi SS, Gibney GT, Gainor JF, Rahma OE, Seiwert TY, Meric-Bernstam F, Blum Murphy MA, Litton JK, Hooper EMD. Hirsch HA, Harvey C, Clancy M, McClure T, Callahan MK. ICONIC: Biologic and clinical activity of first in class ICOS against antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers. 2018 ASCO Annual Meeting, 2018.
20. Rugo HS, Ettl J, Woodward NE, Hurvitz SA, Goncalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roche HH, Im YH, Markova D, Tudor IC, Eiermann W, Blum JL, Hannah AL, Litton JK. EMBRACA: Efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. 2018 ASCO Annual Meeting, 2018.
21. Eiermann W, Rugo HS, Diab S, Ettl J, Hurvitz SA, Goncalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roche HH, Im YH, Markova D, Tudor IC, Blum JL, Hannah AL, Litton JK. Analysis of germline BRCA1/2 mutated (gBRCAmut) hormone receptor-positive (HR+) and triple negative breast cancer (TNBC) treated with talazoparib (TALA). 2018 ASCO Annual Meeting, 2018.
22. Litton J, Rugo HS, Ettl J, Hurvitz S, Goncalves a, Lee KY, Fehrenbacher l, Yerushalmi r, Mina LA, Martin M, Roche H, Im YH, Quek RGW, Tudor IC, Hannah AL, Eirmann W, Blum JL. EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation. 2017 CTRC-AACR San Antonio Breast Cancer Symposium, 2017.
23. Yam C, Huo L, Hess KR, Litton JK, Yang W, Piwnica-Worms H, Mittendorf EA, Ueno NT, Lim B, Murthy RK, Damodaran S, Helgason T, Thompson AM, Santiago L, Candelaria RP, Rauch GM, Adrada BE, Symmans WF, Gilcrease MZ, Moulder SL. Androgen receptor positivity is associated with nodal disease in triple negative breast cancer. 2017 CTRC-AACR San Antonio Breast Cancer Symposium, 2017.
24. Parkes AM, Clifton KK, Al Awadhi A, Oke OC, Warneke CL, Litton JK, Hortobagyi GN. Tumor subtype concordance between breast and bone biopsies in bone only metastasis patients. 2017 CTRC-AACR San Antonio Breast Cancer Symposium, 2017.
25. Ross JL, Woodson AH, Gutierrez Barrera AM, Litton JK. Multi-gene panel testing results in patients with multiple breast cancer primaries. 2017 CTRC-AACR San Antonio Breast Cancer Symposium, 2017.
26. Rauch GM, Zhu H, Li H, Adrada BE, Santiago L, Candelaria RP, Wang H, Leung J, Litton J, Wu Y, Murthy R, Mittendorf EA, Yang W. Association of quantitative MRI features with tumor infiltrating lymphocytes and treatment response prediction in HER2 positive subtype of breast cancer. 2017 CTRC-AACR San Antonio Breast Cancer Symposium, 2017.
27. Yam C, Gutierrez Barrera A, Huang D, Lin X, Litton JK, Arun B. Implications of somatic TP53 and PIK3CA mutations in patients with metastatic breast cancer who underwent germline BRCA testing. 2017 CTRC-AACR San Antonio Breast Cancer Symposium, 2017.
28. Clifton KK, Kimmel J, Yi M, Chad B, Litton J, Debu T, Meghan K. The impact of dose delays and reductions on toxicity and progression free survival (PFS) in patients receiving palbociclib. 2017 CTRC-AACR San Antonio Breast Cancer Symposium, 2017.
29. Rauch GM, Li H, Zhu H, Adrada BE, Santiago L, Candelaria RP, Wang H, Leung J, Thompson A, Litton J, Wu Y, Lim B, Moulder S, Mittendorf EA, Yang W. Quantitative MRI features analysis for differentiation of triple negative and HER2 positive subtypes of breast cancer. 2017 CTRC-AACR San Antonio Breast Cancer Symposium, 2017.
30. Echeverria GV, Cai S, Tu Y, McCoy A, Lau R, Redwood A, Rauch G, Adrada B, Candelaria R, Santiago L, Thompson A, Litton J, Moulder S, Symmans F, Chang JT, Piwnica-Worms H. A molecularly annotated collection of breast cancer patient-derived xenograft models aligned with ongoing clinical trials built from fine needle aspiration samples throughout neoadjuvant treatment. 2017 CTRC-AACR San Antonio Breast Cancer Symposium, 2017.
31. Yam C, Santiago L, Candelaria RP, Adrada BE, Rauch GM, Hess KR, Litton JK, Piwnica-Worms H, Mittendorf EA, Ueno NT, Lim B, Murthy RK, Damodaran S, Helgason T, Huo L, Thompson AM, Gilcrease MZ, Symmans WF, Moulder SL, Yang. Risk of needle-track seeding with serial ultrasound guided biopsies in triple negative breast cancer. 2017 CTRC-AACR San Antonio Breast Cancer Symposium, 2017.
32. Litton JK, Scoggins M, Whitman GJ, Barcenas CH, Moulder SL, Murthy RK, Abouharb S, Adrada B, Helgason T, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Arun B. A feasibility study of neoadjuvant talazoparib for early-stage breast cancer patients with a germline BRCA pathogenic variant: NCT02282345. 2017 ASCO Annual Meeting, 2017.
33. Peace KM, Mittendorf EA, Perez SA, Tzonis P, Pistamaltzian NF, Anastasopoulou EA, Vreeland TJ, Hale DF, Clifton GT, Litton JK, von Hofe E, Ardavanis A, Papamichail M, Peoples GE. Subgroup efficacy evaluation of the AE37 HER2 vaccine in breast cancer patients in the adjuvant setting. 2017 ASCO Annual Meeting, 2017.
34. Clifton K, Barrera AG, Ma J, Bassett RL, Litton JK, Arun B. Adjuvant or neoadjuvant chemotherapy in early stage triple negative breast cancer (TNBC) comparison of outcomes in both BRCA positive and BRCA negative patients. 2017 ASCO Annual Meeting, 2017.
35. Parkes A, Clifton K, Awadhi AA, Oke O, Warneke CL, Litton JK, Hortobagyi GN. Characterization of bone only metastasis (BOM) patients (pts) with respect to tumor subtypes (TS). 2017 ASCO Annual Meeting, 2017.
36. Yam C, Hess KR, Litton JK, Yang WT, Piwnica-Worms H, Mittendorf EA, Ueno NT, Lim B, Murthy RK, Damodaran SK, Helgason T, Huo L. Thompson AM, Gilcrease M, Santiago L, Candelaria RP, Rauch G, Adrada B, Symmans WF, Moulder SL. A randomized, triple negative breast cancer enrolling trial to confirm molecular profiling improves survival (ARTEMIS). 2017 ASCO Annual Meeting, 2017.
37. Murthy RK, Fujii T, Hess KR, Raghavendra AS, Lim B, Barcenas CH, Zhang HA, Chavez-Mac Gregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson AM, Valero V, Tripathy D, Ueno NT. Effect of neoadjuvant pertuzumab-containing regimens on pathologic complete response rates in stage II-III HER2-neu positive breast cancer: A retrospective, single institutional experience. 2017 ASCO Annual Meeting, 2017.
38. Dumbrava EAI, Brusco L, Daniels MS, Wathoo C, Shaw KR, Lu KH, Zheng X, Strong LC, Litton JK, Arun B, Eterovic AK, Piha-Paul SA, Subbiah V, Hong DS, Woodman SE, Mendelsohn J, Yap TA, Mills GB. Chen K, Meric-Bernstam F. Pathogenic variants in DNA damage response (DDR) genes in patients with advanced solid tumors. 2017 ASCO Annual Meeting, 2017.
39. Dumbrava EEI, Brusco L, Daniels MS, Wathoo C, Shaw KR, Lu KH, Zheng X, Strong LC, Litton JK, Arun B, Eterovic AK, Routbort M, Piha-Paul SA, Subbiah V, Hong DS, Kopetz S, Mendelsohn J, Mills GB, Chen K, Meric-Bernstam F. Prevalence of incidental germline pathogenic (PV) and likely pathogenic (LPV) variants in hereditary cancer-related genes identified in matched tumor/normal sequencing of advanced solid tumors. 2017 ASCO Annual Meeting, 2017.
40. Oke O, Warneke CL, Chavez-Mac Gregor M, Milbourne A, Litton JK. Outcomes related to delayed initiation of anti-HER2 therapy in pregnant HER2 positive breast cancer patients. 2017 ASCO Annual Meeting, 2017.
41. Arun B, Elsayegh N, Lin HY, Clifton K, Gutierrez-Barrera AM, Litton JK, Albarracin CT. Breast cancer phenotype in patients with hereditary gene mutations other than BRCA1 and BRCA2. 2017 ASCO Annual Meeting, 2017.
42. Scoggins M, Dogan B, Ma J, Wei W, Song JB, Candelaria RP, Litton JK, Arun B. Short breast MRI screening trial in women at high-risk for breast cancer. 2017 ASCO Annual Meeting, 2017.
43. Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, Adrada BE, Moulder SL, Barcenas CH, Valero V, Booser D, Schwartz Gomez J, Mills GB, Piwnica-Worms H, Arun BK. A pilot study of neoadjuvant talozoparib for early-stage breast cancer patients with a BRCA mutation. ESMO Annual Meeting, 2016.
44. Muse KI, Bednar E, Emborgo TS, Oakley HD, Litton JK, Peterson SK, Lu KH, Arun B. Universal BRCA testing of TNBC and HGSOC and active family outreach to increase identification of at-risk relatives for cascade testing. 2016 ASCO Annual Meeting, 2016.
45. Fujii T, Kogawa T, Dong W, Litton JK, Moulder SL, Tripathy D, Hunt K, Iwamoto T, Pusztai L, Lim B, Shen Y, Ueno NT. New threshold of ER positivity in early stage HER2- breast cancer. 2016 ASCO Annual Meeting, 2016.
46. Rugo HS, Seneviratne L, Beck JT, Glaspy JA, Peguero JA, Pluard TJ, Dhillon N, Hwang LC, Nangia CS, Mayer IA, Meiller TF, Chambers MS, Warsi G, Sweetman RW, Sabo JR, Litton JK. Prevention of everolimus/exemestane (EVE/EXE) stomatitis in postmenopausal (PM) women with hormone receptor-positive (HR+) metastatic breast cancer (MBC) using a dexamethasone-based mouthwash (MW): Results of the SWISH trial. 2016 ASCO Annual Meeting, 2016.
47. Litton JK, Blum JL, Im Y-H, Martin M, Mina L, Roché H, Visco F, Yang X, Lokker NA, Lounsbury DL, Eiermann W. EMBRACA: A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) versus physician's choice in BRCA mutation subjects with locally advanced and/or metastatic breast cancer. 2015 CTRC-AACR San Antonio Breast Cancer Symposium, 2015.
48. Alvarez RH, Koenig KB, Ensor JE, Ibrahim NK, Chavez-MacGregor M, Litton JK, Schwartz Gomez JK, Cyriac A, Krishnamurthy S, Caudle AS, Shaitelman SF, Whitman GJ, Booser DJ, Reuben JM, Valero V. A randomized phase II neoadjuvant (NACT) study of sequential eribulin followed by FAC/FEC-regimen compared to sequential paclitaxel followed by FAC/FEC-regimen in patients (pts) with operable breast cancer not overexpressing HER-2. 2015 CTRC-AACR San Antonio Breast Cancer Symposium, 2015.
49. Fujii T, Kogawa T, Dong W, Moulder S, Litton JK, Tripathy D, Lim B, Shen Y, Ueno NT. Association between quantitative values of estrogen receptor expression level and pathological complete response in human epidermal growth factor 2-negative breast cancer: Should the clinical definition of triple-negative breast cancer be redefined?. 2015 CTRC-AACR San Antonio Breast Cancer Symposium, 2015.
50. Emborgo T, Muse KI, Bednar E, Oakley HD, Litton J, Lu KH, Arun BK. Universal BRCA testing and family outreach for women with triple negative breast cancer. 2015 CTRC-AACR San Antonio Breast Cancer Symposium, 2015.
51. Greene JM, Schneble EJ, Perez S, Murray JL, Berry JS, Trappey AF, Hale DF, Vreeland TJ, Clifton GT, Ardavanis A, Litton JK, Shumway NM, Papamichail M, Peoples GE, Mittendorf EA. Final pre-specified analysis of the phase II trial of the GP2+GM-CSF peptide vaccine in high risk breast cancer patients to prevent recurrence. 2015 CTRC-AACR San Antonio Breast Cancer Symposium, 2015.
52. Mitri ZI, Ueno NT, Yang W, Valero V, Litton JK, Murthy RK, Ibrahim NK, Arun BK, Mittendorf EA, Hunt KK, Meric-Bernstam F, Thompson A, Piwnica-Worms H, Tripathy D, Symmans F, Moulder-Thompson S. Women's triple-negative, first-line treatment: Improving outcomes in triple-negative breast cancer using molecular triaging and diagnostic imaging to guide neoadjuvant therapy. 2015 CTRC-AACR San Antonio Breast Cancer Symposium, 2015.
53. Basho RK, Gilcrease M, Murthy RK, Helgason T, Booser DJ, Karp DD, Meric-Bernstam F, Wheler JJ, Valero V, Albarracin C, Litton J, Chavez-MacGregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder S. Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer (TNBC): Evidence of efficacy and proof of concept from a phase I trial with dose expansion of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab. 2015 CTRC-AACR San Antonio Breast Cancer Symposium, 2015.
54. Litton JK, Blum JL, Im Y-H, Martin M, Mina LA, Roche HH, Rugo HS, Visco F, Zhang C, Lokker NA, Lounsbury DL, Eiermann W. A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). 2015 ASCO Annual Meeting, 2015.
55. Moulder SL, Ueno NT, Yang WT, Ensor J, Valero V, Litton JK, Murthy RK, Ibrahim NK, Arun B, Mittendorf EA, Hunt K, Meric-Bernstam F, Thompson AM, Piwnica-Worms H, Tripathy D, Symmans WF. Women’s triple-negative, first-line treatment: Improving outcomes in triple-negative breast cancer (TNBC) using molecular triaging and diagnostic imaging to guide neoadjuvant therapy (NACT). 2015 ASCO Annual Meeting, 2015.
56. Ardic C, Gutierrez-Barrera AM, Elsayegh N, Song J, Profato J, Litton JK, Giordano SH, Tripathy D, Arun B. Predictors of BRCA mutation in male breast cancer. 2015 ASCO Annual Meeting, 2015.
57. Vila J, Bassett RL, Mittendorf EA, Bedrosian I, Shaitelman SF, Stauder MC, Chavez-Mac Gregor M, Litton JK, Yang WT, Huo L, Kuerer HM, Hunt K, Caudle AS. A nomogram to predict axillary response to neoadjuvant chemotherapy in clinically node positive breast patients. 2015 ASCO Annual Meeting, 2015.
58. Fujii T, Kogawa T, Wei C, Fouad TM, Harano K, Park YS, Lim B, Tripathy D, Ueno NT, Litton JK. Association of body mass index with survival outcome in three breast cancer subtypes. 2015 ASCO Annual Meeting, 2015.
59. Basho RK, Gagliato DD, Ueno NT, Alvarez RH, Wathoo C, Chen H, Wei C, Sahin AA, Roy-Chowdhuri S, Moulder SL, Chavez-Mac Gregor M, Litton JK, Valero V, Luthra R, Shaw KR, Mendelsohn J, Mills GB, Tripathy D, Meric-Bernstam F. Clinical outcomes based on multigene profiling in metastatic breast cancer patients. 2015 ASCO Annual Meeting, 2015.
60. Meric-Bernstam F, Brusco L, Daniels MS, Strong LC, Shaw KR, Lu, KH, QU Y,Lara-Guerra H, Litton JK, Zhao H, Eterovic AK, Arun B, Routbort M, Janku F, Davies MA, Kopetz S, Mendelsohn J, Mills GB, Chen K. Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program. 2015 ASCO Annual Meeting, 2015.
61. Kogawa T, Fouad TM, Wei C, El-Zein RA, Masuda H, Chavez-Mac-Gregor M, Melhem-Bertrandt A, Litton JK, Brewster AM, Alvarez RH, Hortobagyi GN, Vicente V, Ueno NT, Theriault RL. Association between body mass index change during neoadjuvant chemotherapy and pathologic complete response and overall survival in patients with inflammatory breast cancer or locally advanced non-inflammatory breast cancer. 2014 CTRC-AACR San Antonio Breast Cancer Symposium, 2014.
62. Murthy RK, Schover LR, Theriault RL, Valero V, Woodard TL, Hodge S, Litton JK. Women with pregnancy-associated early breast cancer achieve improved emotional well-being as a result of their cancer experience. 2014 CTRC-AACR San Antonio Breast Cancer Symposium, 2014.
63. Chavez-Mac Gregor M, Lei X, Litton JK, Melhem-Bertrand A, Giordano SH, Masuda H, Ueno N, Gabriel HN, Valero V. Statin use and outcome among breast cancer patients treated with neoadjuvant systemic chemotherapy. 2014 CTRC-AACR San Antonio Breast Cancer Symposium, 2014.
64. IIsaacs C, Ozguroglu M, Jerusalem G, Xu B, Láng I, O'Regan R, White M, Fasolo A, Litton J, Toi M, Shen K, Andre F, Vuylsteke P, Zhang Y, Zhang J, Taran T, Wilks S. BOLERO-3: Quality-of-life maintained in patients with metastatic breast cancer treated with everolimus plus trastuzumab plus vinorelbine. 2014 CTRC-AACR San Antonio Breast Cancer Symposium, 2014.
65. Elsayegh N, Gutierrez-Barrera A, Baum G, Muse K, Jackson M, Woodson A, Jessica P, Kuerer H, Litton J, Arun B. Factors associated with prophylactic mastectomy among BRCA-positive patients with no personal history of breast cancer. 2014 CTRC-AACR San Antonio Breast Cancer Symposium, 2014.
66. Rugo HS, Chambers MS, Litton J, Mayer I, Rogerio J, Demars L, Geronimo J, Warsi G, Meiller TF. Phase 2, single arm study of a steroid-based mouthwash to prevent stomatitis in women with hormone receptor–positive advanced breast cancer treated with everolimus plus exemestane. 2014 CTRC-AACR San Antonio Breast Cancer Symposium, 2014.
67. Sanford RA, Song J, Gutierrez-Barrera AM, Litton JK, Bedrosian I, Albarracin CT, Valero V, Arun B; The University of Texas MD Anderson Cancer Center, Houston, TX. Incidence of germline BRCA mutation in patients with ER-low positive/PR negative/HER-2 neu negative tumors. 2014 ASCO Breast Cancer Symposium, 2014.
68. Sanford RA, Song J, Gutierrez-Barrera AM, Litton JK, Bedrosian I, Albarracin CT, Valero V, Arun B; The University of Texas MD Anderson Cancer Center, Houston, TX. Incidence of germline BRCA mutation in patients with ER-low positive/PR negative/HER-2 neu negative tumors. 2014 ASCO Breast Cancer Symposium, 2014.
69. Elsayegh N, Lin HY, Gutierrez-Barrera AM, Profato J, Litton JK, Kuerer HM, Hortobagyi GN, Arun B; The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas MD Anderson Cancer Center, HOUSTON, TX. Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who tested negative for a BRCA mutation. 2014 Breast Cancer Symposium, 2014.
70. Schneble EJ, Perez SA, Murray JL, Berry JS, Trappey AF, Vreeland TJ, Hale DF, Greene JM, Clifton GT, Ardavanis A, Litton JK, Ponniah S, Shumway NM, Papamichail M, Peoples GE, Mittendorf EA; San Antonio Military Medical Center, San Antonio, TX; Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece; The University of Texas MD Anderson Cancer Center, Houston, TX; Saint Savvas Anticancer Hospital, Athens, Greece; Cancer Vaccine Development Program, United States Military Cancer Institute, USUHS, Bethesda, MD; Cancer Immunology and Immunotherapy Center, Athens, Greece; San Antonio Military Medical Center, Fort Sam Houston, TX. Primary analysis of the prospective, randomized, phase II trial of GP2+GM-CSF vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients. 2014 Breast Cancer Symposium, 2014.
71. Schneble EJ, Perez SA, Murray JL, Berry JS, Trappey AF, Vreeland TJ, Hale DF, Greene JM, Clifton GT, Ardavanis A, Litton JK, Ponniah S, Shumway NM, Papamichail M, Peoples GE, Mittendorf EA; San Antonio Military Medical Center, San Antonio, TX; Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece; The University of Texas MD Anderson Cancer Center, Houston, TX; Saint Savvas Anticancer Hospital, Athens, Greece; Cancer Vaccine Development Program, United States Military Cancer Institute, USUHS, Bethesda, MD; Cancer Immunology and Immunotherapy Center, Athens, Greece; San Antonio Military Medical Center, Fort Sam Houston, TX. Primary analysis of the prospective, randomized, phase II trial of GP2+GM-CSF vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients. 2014 Breast Cancer Symposium, 2014.
72. Dalal S, Hui D, Yeung SJ, Chisholm GB, Ihenacho IS, Ogunti R, De la Cruz M, Vidal M, Bedi D, Dev R, Bruera E, Litton JK: The University of Texas MD Anderson Cancer Center, Houston, TX. Association between visceral adiposity, BMI, and clinical outcomes in postmenopausal women with operable breast cancer. 2014 ASCO Annual Meeting, 2014.
73. Rugo HS, Chambers MS, Litton JK, Mayer IA, Rogerio JW, DeMars LR, Geronimo J, Warsi G, Meiller TF; University of California San Francisco Medical Center, San Francisco, CA; The University of Texas MD Anderson Cancer Center, Houston, TX; Vanderbilt-Ingram Cancer Center, Vanderbilt University, School of Medicine, Nashville, TN; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Greenebaum Cancer Center, University of Maryland, Baltimore, MD. Prevention of stomatitis in patients with hormone receptor–positive advanced breast cancer treated with everolimus plus exemestane: A phase II study of a steroid-based mouthwash. 2014 ASCO Annual Meeting, 2014.
74. Mitri ZI, Jackson M, Garby C, Giordano SH, Hortobagyi GN, Singletary C, Hashmi SS, Arun B, Litton JK; The University of Texas MD Anderson Cancer Center, Houston, TX; Baylor Health, Dallas, TX; The University of Texas Health and Science Center at Houston, Houston, TX. BRCAPRO 6.0 model validation in male patients presenting for BRCA testing. 2014 ASCO Annual Meeting, 2014.
75. Murthy RK, Chen H, Wei S, Jackson M, Woodson AH, Litton JK, Arun B, Valero V, Barcenas CH; The University of Texas MD Anderson Cancer Center, Houston, TX. Genetic testing referral patterns and clinical outcomes among high-risk breast cancer survivors. 2014 ASCO Annual Meeting, 2014.
76. Kogawa T, Fouad TM, Wei C, El-Zein RA, Masuda H, Chavez-Mac-Gregor M, Melhem-Bertrandt A, Litton JK, Brewster AM, Alvarez RH, Hortobagyi GN, Vicente V, Ueno NT, Theriault RL. The University of Texas MD Anderson Cancer Center, Houston, TX. Association between body mass index change during neoadjuvant chemotherapy and pathologic complete response and overall survival in patients with inflammatory breast cancer or locally advanced non-inflammatory breast cancer. 2013 CTRC-AACR San Antonio Breast Cancer Symposium, 2013.
77. Afrough A, Lin H, Gutierrez-Barrera AM, Litton JK, Valero V, Arun B; The University of Texas MD Anderson Cancer Center, Houston, TX. Outcomes of HER2-positive nonmetastatic breast cancer patients with or without deleterious BRCA mutations after trastuzumab treatment. 2013 ASCO Annual Meeting, 2013.
78. Kelly CM, Beamish R, McCaffrey J, Smith M, Crown J, O'Connor M, McGee SF, O'Reilly S, Moylan EJ, Gonzalez-Angulo AM, Litton JK, Pusztai L, Kelly CM; Department of Medical Oncology, Cork University Hospital, Cork, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Department of Medical Oncology, Mater Misericordiae University Hospital, Dublin, Ireland; Department of Medical Oncology, St. Vincent's University Hospital, Dublin, Ireland; Waterford Regional Hospital, Waterford, Ireland; The University of Texas MD Anderson Cancer Center, Houston, TX; Yale Cancer Center, New Haven, CT. A comparative analysis of distant recurrence risk assessments by Oncotype DX recurrence score alone and integrated with clinicopathologic factors in early-stage breast cancer. 2013 ASCO Annual Meeting, 2013.
79. Patil R, Clifton GT, Litton JK, Shumway NM, Vreeland TJ, Berry JS, Trappey AF, Ponniah S, Peoples GE, Mittendorf EA; Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY; Blanchfield Army Community Hospital, Fort Campbell, KY; The University of Texas MD Anderson Cancer Center, Houston, TX; San Antonio Military Medical Center, Fort Sam Houston, TX; Brooke Army Medical Center, San Antonio, TX; Cancer Vaccine Development Program, United States Military Cancer Institute, USUHS, Bethesda, MD; Department of Surgery, Brooke Army Medical Center, Fort Sam Houston, TX. Safety and efficacy of the HER2-derived GP2 peptide vaccine in combination with trastuzumab for breast cancer patients in the adjuvant setting. 2013 ASCO Annual Meeting, 2013.
80. Campone M, Lebrun F, Noguchi S, Pritchard KI, Burris HA, Beck JT, Ito Y, Yardley DA, Bachelot TD, Pistilli B, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Litton JK, Panneerselvam A, El-Hashimy M, Taran T, Gnant M; CLCC René Gauducheau, Centre de Recherche en Cancerologie, Nantes Saint Herblain, France; Jules Bordet Institute, Brussels, Belgium; Department of Breast and Endocrine Surgery, Osaka University, Osaka, Japan; Odette Cancer Centre, Sunnybrook Health Sciences Centre; University of Toronto, Toronto, ON, Canada; Sarah Cannon Research Institute, Nashville, TN; Highlands Oncology Group, Fayetteville, AR; Cancer Institute Hospital, Japanese Foundation for Cancer Research Breast Medical Oncology, Breast Oncology Center, Tokyo, Japan; Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Centre Léon Bérard, Lyon, France; Ospedale di Macerata, Macerata, Italy; Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic; Masaryk Memorial Cancer Institute, Brno, Czech Republic; Arena Oncology Associates, Lake Success, NY; Orbis Medical Center, Sittard, Netherlands; Horizon Oncology Research, Lafayette, IN; The University of Texas MD Anderson Cancer Center, Houston, TX; Novartis Pharmaceuticals Corp, Florham Park, NJ; Novartis Pharmaceuticals Corp, East Hanover, NJ; Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Characterization of patients who received prior chemotherapy for advanced breast cancer (ABC) in BOLERO-2. 2013 ASCO Annual Meeting, 2013.
81. Elsayegh N, Gutierrez-Barrera AM, Muse KI, Lin H, Turco DL, Litton JK, Kuerer HM, Arun B; University of Texas M. D. Anderson Cancer Center, Houston, TX. Predictors of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ (DCIS) who underwent evaluation for BRCA genetic testing. 2012 ASCO Annual Meeting, 2012.
82. Chae YK, Brown EN, Lei X, Melhem-Bertrandt A, Giordano SH, Litton JK, Hortobagyi GN, Gonzalez-Angulo AM, Chavez-MacGregor M; University of Texas M. D. Anderson Cancer Center, Houston, TX. ACE inhibitors and angiotensin receptor blockers use and breast cancer outcomes in patients treated with neoadjuvant systemic chemotherapy. 2012 ASCO Annual Meeting, 2012.
83. Milbourne A, Sun CC, Fanale MA, Theriault RL, Rimes SA, Litton JK, Ramirez MM; University of Texas M. D. Anderson Cancer Center, Houston, TX; Baylor School of Medicine, Houston, TX. Pregnancy outcomes in women with cancer. 2012 ASCO Annual Meeting, 2012.
84. Dallas NA, Yi M, Hunt K, Shah RR, Kuerer HM, Litton JK, Wu Y, Caudle AS, Meric-Bernstam F, Sahin AA, Mittendorf EA; University of Texas M. D. Anderson Cancer Center, Houston, TX. Evaluation of the stage IB designation of the 7th edition of the AJCC staging system. 2012 ASCO Annual Meeting, 2012.
85. Yennurajalingam S, Frisbee-Hume S, Delgado-Guay MO, Bull J, Phan AT, Tannir NM, Litton JK, Palmer JL, Reddy AS, Hui D, Dalal S, Massie L, Vadhan-Raj S, Reddy SK, Reuben JM, Bruera E; University of Texas M. D. Anderson Cancer Center, Houston, TX; Four Seasons Hospice, Flat Rock, NC. Dexamethasone (DM) for cancer-related fatigue: A double-blinded, randomized, placebo-controlled trial. 2012 ASCO Annual Meeting, 2012.
86. Dawood SS, Dent RA, Gupta S, Litton JK, Mustafa R, Cortes J, Mittendorf EA, Gonzalez-Angulo AM, Buchholz TA; Dubai Hospital, Dubai, United Arab Emirates; National Cancer Centre Singapore, Singapore, Singapore; Tata Memorial Hospital, Mumbai, India; University of Texas M. D. Anderson Cancer Center, Houston, TX; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain. Impact of surgery and radiation of the primary among women with de novo stage IV breast cancer. 2012 ASCO Annual Meeting, 2012.
87. Litton JK, Etzel CJ, Jackson MA, Muse KI, Turco D, Schover LR, Theriault RL, Mattair D, Lu KH, Hortobagyi GN, Arun BK. Breast cancer, BRCA mutations and attitudes regarding pregnancy and preimplantation genetic diagnosis. 2011 CTRC-AACR San Antonio Breast Cancer Symposium, 2011.
88. Muse KI, Elsayegh N. Gutierrez-Barrera AM, Kuerer H, Valero V, Litton JK, Hortobagyi GN, Arun BK. Evaluation of BRCAPro Risk assessment model in patients with ductal carcinoma in situ. 2011 CTRC-AACR San Antonio Breast Cancer Symposium, 2011.
89. Turco DL, Elsayegh N, Litton JK Hortobagyi GN, Arun B. Testing women with invasive lobular breast cancer for BRCA mutations. 2011 CTRC-AACR San Antonio Breast Cancer Symposium, 2011.
90. Arun B, Biswas S, Tankhiwale N, Blackford AL, Gutierrez-Barrera AM, Litton JK, Hortobagyi GN, Amos CI, Parmigiani G; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of North Texas Health Science Center, Fort Worth, TX; The Johns Hopkins University School of Medicine, Baltimore, MD; Dana-Farber Cancer Institute, Boston, MA. Assessing the added value of breast tumor markers in breast cancer genetic risk prediction model BRCAPRO. 2011 ASCO Breast Cancer Symposium, 2011.
91. Jackson M, Mattair D, Lin H, Gutierrez-Barrera AM, Elsayegh N, Litton JK, Hortobagyi GN, Arun B; University of Texas M. D. Anderson Cancer Center, Houston, TX. Identifying genomic rearrangements in BRCA1 and BRCA2 in high-risk individuals for hereditary breast and ovarian cancer. 2011 ASCO Breast Cancer Symposium, 2011.
92. Litton JK, Hodge S, Mattair D, Ramirez MM, Morrow PK, Gonzalez-Angulo AM, Barnett CM, Hortobagyi GN, Theriault RL. Outcomes of children exposed to chemotherapy in utero for breast cancer. 2011 ASCO Annual Meeting, 2011.
93. Dawood SS, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM; Dubai Hospital, Dubai, United Arab Emirates; University of Texas M. D. Anderson Cancer Center, Houston, TX; M. D. Anderson Cancer Center, Houston, TX. Effect of body mass index on survival outcome among women with early-stage, triple-negative breast cancer. 2011 ASCO Annual Meeting, 2011.
94. Chavez-MacGregor M, Lei X, Litton JK, Melhem A, Mittendorf EA, Meric-Bernstam F, Sahin AA, Valero V, Hortobagyi GN, Gonzalez-Angulo AM; University of Texas M. D. Anderson Cancer Center, Houston, TX; M. D. Anderson Cancer Center, Houston, TX. Predictors of recurrence among patients with breast cancer who achieved a pathologic complete response (pCR) after neoadjuvant systemic chemotherapy. 2011 ASCO Annual Meeting, 2011.
95. Morrow PK, Broxson AC, Munsell M, Basen-Engquist K, Rosenblum CK, Nguyen LH, Schover LR, Hahn K, Litton JK, Hortobagyi GN; University of Texas M. D. Anderson Cancer Center, Houston, TX. Long-term effects of the diagnosis and treatment of breast cancer upon young breast cancer survivors. 2011 ASCO Annual Meeting, 2011.
96. Holland MG, McCampbell A, Litton JK, Theriault RL, Ramirez MM; University of Texas Health Science Center at Houston, Houston, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX. Alterations in breast cancer resistance protein in human placentas exposed to chemotherapy. 2011 ASCO Annual Meeting, 2011.
97. Lei X, Dawood SS, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM; University of Texas M. D. Anderson Cancer Center, Houston, TX; Dubai Hospital, Dubai, United Arab Emirates; M. D. Anderson Cancer Center, Houston, TX. Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. 2011 ASCO Annual Meeting, 2011.
98. Elsayegh N, Bayraktar S, Gutierrez-Barrera AM, Lin H, Kuerer HM, Muse KI, Ready K, Litton JK, Meric-Bernstam F, Hortobagyi GN, Arun B; University of Texas M. D. Anderson Cancer Center, Houston, TX; Jackson Memorial Hospital, University of Miami, Miami, FL. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. 2011 ASCO Annual Meeting, 2011.
99. Gonzalez-Angulo AM, Green MC, Murray JL, Palla SL, Koenig KH, Brewster AM, Valero V, Ibrahim NK, Moulder SL, Litton JK, Crawford DJ, Flores PR, Dryden MJ, Symmans WF, Giordano SH, Pusztai L, Buzdar A, Mills GB, Hortobagyi GN, Meric-Bernstam F; M. D. Anderson Cancer Center, Houston, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; Department of Investigational Cancer Therapeutics (Phase I Program), University of Texas M. D. Anderson Cancer Center, Houston, TX. Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC). 2011 ASCO Annual Meeting, 2011.
100. Melhem-Bertrandt A, Reddy KJ, Gutierrez-Barrera AM, Litton JK, Strong LC, Olopade OI, Hortobagyi GN, Arun BK. Increased rate of HER2-positive breast cancers among women with germline TP53 mutations. 2010 CTRC-AACR San Antonio Breast Cancer Symposium, 2010.
101. Chavez-MacGregor M, Brown EN, Lei X, Hsu L, Meric-Bernstam F, Litton JK, Mittendorf EA, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Bisphosphonates and pathologic complete response to neoadjuvant chemotherapy in patients with breast cancer. 2010 CTRC-AACR San Antonio Breast Cancer Symposium, 2010.
102. Arun BK, Gutierrez-Barrera AM, Akar U, Litton JK, Albarracin C, Gonzalez-Angulo AM, Hortobagyi GN. Outcome of triple negative breast cancer in patients with or without deleterious BRCA mutations. 2010 CTRC-AACR San Antonio Breast Cancer Symposium, 2010.
103. Pusztai L, Moulder S, Litton JK, Valero V, Ueno N, Melhem-Bertrandt A, Morrow PK, Dotter K, Mattair D, Strauss L, Hortobagyi GN, Qi Y, Symmans WF. Prospective testing of three different gene-signatures for patient selection for dasatinib therapy in metastatic breast cancer. 2010 CTRC-AACR San Antonio Breast Cancer Symposium, 2010.
104. Litton JK, Warneke CL, Hahn KM, Palla SL, Kuerer HM, Perkins GH, Middleton LP, Gonzalez-Angulo AM, Hortobagyi GN, Theriault RL. Case-control analysis of patients treated with chemotherapy during pregnancy for breast cancer. 2010 ASCO Breast Cancer Symposium, 2010.
105. Litton JK, Warneke CL, Hahn K, Palla SL, Kuerer HM, Perkins GH, Middleton LP, Gonzalez-Angulo AM, Hortobagyi GN, Theriault RL. Case-control analysis of patients (pts) treated with chemotherapy during pregnancy for breast cancer (BC). 2010 ASCO Breast Cancer Symposium, 2010.
106. Gonzalez-Angulo AM, Chen H, Timms K, Litton JK, Potter J, Lanchbury JS, Arun B, Hortobagyi GN, Do K, Meric-Bernstam F; University of Texas M. D. Anderson Cancer Center, Houston, TX; Myriad Genetics, Inc., Salt Lake City, UT. Incidence and outcome of BRCA mutation carriers with triple receptor-negative breast cancer (TNBC). 2010 ASCO Breast Cancer Symposium, 2010.
107. Gutierrez-Barrera AM, Turco DL, Alvarez RH, Litton JK, Valero V, Hortobagyi GN, Arun B; University of Texas M. D. Anderson Cancer Center, Houston, TX. BRCA mutations in women with inflammatory breast cancer. 2010 ASCO Breast Cancer Symposium, 2010.
108. Ready K, Gutierrez-Barrera AM, Litton JK, Lu KH, Hortobagyi GN, Arun B; University of Texas M. D. Anderson Cancer Center, Houston, TX. Obesity, smoking, alcohol consumption, and risk of multiple primary breast cancers in BRCA1 and BRCA2 mutation carriers. 2010 ASCO Breast Cancer Symposium, 2010.
109. Litton JK, Chen H, Mittendorf EA, Meric-Bernstam F, Chavez-MacGregor M, Woodward WA, Sahin A, Theriault RL, Hortobagyi GN, Gonzalez-Angulo AM. Outcomes differences in tumors < 1cm by age and breast cancer subtype. 2010 ASCO Annual Meeting, 2010.
110. Pusztai L, Moulder SL, Litton JK, Valero V, Ueno NT, Morrow PH, Dotter K, Mattair D, Strauss LC, Symmans WF; University of Texas M. D. Anderson Cancer Center, Houston, TX; Bristol-Myers Squibb, Wallingford, CT. Gene-signature-based patient selection for dasatinib therapy in metastatic breast cancer (MBC). 2010 ASCO Annual Meeting, 2010.
111. Guarneri V, Chavez-MacGregor M, Hsu L, Symmans WF, J. K. Litton, Mittendorf EA, Conte PF, Hortobagyi GN, Gonzalez-Angulo AM; Department of Oncology, Hematology, and Respiratory Diseases, Modena University Hospital, Modena, Italy; University of Texas M. D. Anderson Cancer Center, Houston, TX; Department of Oncology and Hematology, University Hospital, Modena, Italy. Use of Ki-67 in residual disease following preoperative chemotherapy to predict of recurrence and death in breast cancer patients. 2010 ASCO Annual Meeting, 2010.
112. Jackson M, Brandt A, Gutierrez-Barrera A, Meric-Bernstam F, Litton JK, Lu KH, Hortobagyi GN, Arun B; University of Texas M. D. Anderson Cancer Center, Houston, TX. Effects of ethnicity on genotype-phenotype correlations in individuals with a BRCA1 or BRCA2 mutation. 2010 ASCO Annual Meeting, 2010.
113. Chavez-MacGregor M, Hubbard R, Meric-Bernstam F, Shinde SS, Litton JK, Woodward WA, Valero V, Hortobagyi GN, Symmans WF, Gonzalez-Angulo AM; University of Texas M. D. Anderson Cancer Center, Houston, TX; Division of Pathology, University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Illinois at Urbana-Champaign, Urbana, IL. Residual cancer burden (RCB) in breast cancer patients treated with taxane- and anthracycline-based neoadjuvant chemotherapy: The effect of race. 2010 ASCO Annual Meeting, 2010.
114. Meric-Bernstam F, Gutierrez-Barrera A, Litton JK, Mellor-Crummey L, Ready K, Gonzalez-Angulo AM, Lu KH, Hortobagyi GN, Arun B; University of Texas M. D. Anderson Cancer Center, Houston, TX. Mutation position in BRCA-associated breast cancers. 2010 ASCO Annual Meeting, 2010.
115. Yu TK, Tereffe W, Bedrosian I, Eskambi SH, Strom EA, Litton JK, Gonzalez-Angulo AM, Buchholz TA, Hunt KK, Mittendorf EA; M. D. Anderson Cancer Center, Houston, TX. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. 2009 CTRC-AACR San Antonio Breast Cancer Symposium, 2009.
116. Litton JK, Ready K, Gutierrez-Barrera A. Earlier age of onset of BRCA mutation-related cancers in subsequent generations. 2009 ASCO Breast Cancer Symposium, 2009.
117. Chavez-MacGregor M, Litton JK, Huiquin C, Meric-Bernstam F, Hudis CA, Wolff A, Valero V, Hortobagyi GN, Bondy ML, Gonzalez-Angulo AM; University of Texas, M. D. Anderson Cancer Center, Houston, TX; Memorial Sloan-Kettering Cancer Center, New York, NY; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD. Race and pathologic complete response (pCR) in breast cancer patients receiving anthracycline and taxane-based neoadjuvant chemotherapy. 2009 ASCO Breast Cancer Symposium, 2009.
118. Silberfein EJ, Hunt KK, Broglio K, Shen J, Sahin A, Le-Petross H, Oh J, Litton JK, Hwang RF, Mittendorf EA; M. D. Anderson Cancer Center, Houston, TX. Clinicopathologic factors associated with involved margins following breast conserving surgery for invasive lobular carcinoma (ILC). 2009 ASCO Annual Meeting, 2009.
119. Ready, Gutierrez-Barrera AM, Litton JK, Meric-Bernstam F, Gonzalez-Angulo AM, Hortobagyi GN, Arun B. Racial differences in the use of contralateral prophylactic mastectomy among women undergoing BRCA1/BRCA2 genetic testing. 2009 ASCO Annual Meeting, 2009.
120. Litton JK, Chen JQ, Warneke C, Zhang HZ, Berenstein N, Sahin A, Bondy ML, Hortobagyi GN, Murray JL, Radvany L. TRPS-1 in breast cancer. 2008 CTRC-AACR San Antonio Breast Cancer Symposium, 2008.
121. Rakkhit R, Broglio K, Peintinger F, Cardoso F, Hanrahan E, Litton J, Sahin A, Larsimont D, Meric-Bernstam F, Buchholz T, Valero V, Theriault R, Piccart M, Hortobagyi GN, Ravdin P, Gonzalez-Angulo AM. Significant increased recurrence rates among breast cancer patients with HER2-positiveT1abN0M0 tumors. 2008 CTRC-AACR San Antonio Breast Cancer Symposium, 2008.
122. Arun B, Atchley D, Litton JK, Pusztai L, Valero V, Hortobagyi GN, Albarracin CT. Response to neoadjuvant chemotherapy in BRCA1- and BRCA2-related breast cancers. 2008 ASCO Annual Meeting, 2008.
123. Litton JK, Gonzalez-Angulo AM, Warkene CL, Kau SW, Buzdar AU, Bondy M, Mahabir S, Hortobagyi GN, Brewster A. Body mass index and response to neoadjuvant chemotherapy. 2007 ASCO Annual Meeting, 2007.
124. Litton JK, Westin KN, Ready K, Sun CC, Peterson SK, Meric-Bernstam F, Bodurka DC, Lu KH, Hortobagyi GN, Arun BA. Perception of screening and risk-reduction surgeries in patients tested for a BRCA mutation. 2007 CTRC-AACR San Antonio Breast Cancer Symposium, 2007.

Letters to the Editor

1. Litton JK, Lee JH, Arun BK. Reply to BRCA2-Associated Pancreatic Cancer and Current Screening Guidelines. Cancer 121: 3047, 2015.
2. Theriault RL, Litton JK. Reply to D. Crivellari et A. J Clin Oncol 32: 256-7, 2014.